NanoViricides (NNVC) 10-Q15 May 152015 Q3 Quarterly reportFinancial data

Company Profile

Document_And_Entity_Informatio

Document And Entity Information	9 Months Ended
Document And Entity Information	Mar. 31, 2015	15-May-15
Document Information [Line Items]
Entity Registrant Name	NANOVIRICIDES, INC.
Entity Central Index Key	1379006
Current Fiscal Year End Date	-24
Entity Filer Category	Accelerated Filer
Trading Symbol	NNVC
Entity Common Stock, Shares Outstanding		57,150,000
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Mar-15
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2015

Balance_Sheets

Balance Sheets (USD $)	Mar. 31, 2015	Jun. 30, 2014
CURRENT ASSETS:
Cash and cash equivalents	$33,919,404	$36,696,892
Prepaid expenses	308,604	108,089
Prepaid expenses - related parties	66,100	0
Other current assets	0	150,000
Total Current Assets	34,294,108	36,954,981
PROPERTY AND EQUIPMENT
Property and equipment	12,300,894	6,736,742
Accumulated depreciation	-1,393,982	-1,239,986
Property and equipment, net	10,906,912	5,496,756
TRADEMARK AND PATENTS
Trademark and Patents	458,954	458,954
Accumulated amortization	-57,149	-50,696
Trademark and patents, net	401,805	408,258
SECURITY DEPOSIT	0	1,000,000
Total Assets	45,602,825	43,859,995
CURRENT LIABILITIES:
Accounts payable	23,375	376,446
Accounts payable - related parties	0	49,455
Accrued expenses	125,054	91,838
Deferred interest payable	375,000	0
Total Current Liabilities	523,429	517,739
LONG TERM LIABILITIES:
Deposit for debenture	0	5,000,000
Total Long Term Liabilities	13,218,014	19,972,953
Total Liabilities	13,741,443	20,490,692
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY:
Common stock, $0.001 par value; 85,714,285 shares authorized; 57,150,415 and 54,620,993 shares issued and outstanding, respectively	57,150	54,621
Additional paid-in capital	84,982,686	75,212,888
Accumulated deficit	-53,181,861	-51,901,400
Total Stockholders' Equity	31,861,382	23,369,303
Total Liabilities and Stockholders' Equity	45,602,825	43,859,995
Warrant [Member]
LONG TERM LIABILITIES:
Derivative liability	4,611,472	5,235,682
Series B Debentures [Member]
LONG TERM LIABILITIES:
Deposit for debenture	4,525,729	4,037,568
Derivative liability	930,940	5,699,703
Series C Debentures [Member]
LONG TERM LIABILITIES:
Deposit for debenture	2,340,568	0
Derivative liability	809,305	0
Series A Convertible Preferred Stock [Member]
STOCKHOLDERS' EQUITY:
Preferred stock	3,407	3,194
Series B Convertible Preferred Stock [Member]
STOCKHOLDERS' EQUITY:
Preferred stock	0	0
Series C Convertible Preferred Stock [Member]
STOCKHOLDERS' EQUITY:
Preferred stock	$0	$0

Balance_Sheets_Parenthetical

Balance Sheets [Parenthetical] (USD $)	Mar. 31, 2015	Jun. 30, 2014
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	85,714,285	85,714,285
Common stock, shares issued	57,150,415	54,620,993
Common stock, shares, outstanding	57,150,415	54,620,993
Series A Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	4,000,000	4,000,000
Preferred stock, shares issued	3,406,085	3,193,079
Preferred stock, shares outstanding	3,406,085	3,193,079
Series B Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	2,857,143	2,857,143
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Series C Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Statements_of_Operations

Statements of Operations (USD $)	3 Months Ended		9 Months Ended
Statements of Operations (USD $)	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
OPERATING EXPENSES
Research and development	$546,464	$625,737	$2,274,310	$2,930,436
General and administrative	576,173	607,628	2,352,115	1,943,123
Total operating expenses	1,122,637	1,233,365	4,626,425	4,873,559
LOSS FROM OPERATIONS	-1,122,637	-1,233,365	-4,626,425	-4,873,559
OTHER INCOME (EXPENSE):
Interest income	35,009	54,789	156,035	78,850
Interest expense	-1,920,268	-2,725,716	-2,412,712	-2,972,216
Discount on convertible debentures	-297,276	-143,051	-860,454	-419,305
Change in fair value of derivatives	3,054,154	5,371,197	6,463,095	1,585,067
Other income (expense), net	871,619	2,557,219	3,345,964	-1,727,604
(LOSS) INCOME BEFORE INCOME TAX PROVISION	-251,018	1,323,854	-1,280,461	-6,601,163
INCOME TAX PROVISION	0	0	0	0
NET (LOSS) INCOME	($251,018)	$1,323,854	($1,280,461)	($6,601,163)
NET (LOSS) INCOME PER COMMON SHARE
Basic (in dollars per share)	$0	$0.02	($0.02)	($0.13)
Diluted (in dollars per share)	($0.02)	($0.02)	($0.07)	($0.13)
Weighted average common shares outstanding
Basic (in shares)	56,941,122	53,318,736	56,356,105	50,307,984
Diluted (in shares)	59,607,788	55,033,023	59,022,772	50,307,984

Statement_of_Changes_in_Stockh

Statement of Changes in Stockholders' Equity (USD $)	Total	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]
Balance at Jun. 30, 2014	$23,369,303	$3,194	$54,621	$75,212,888	($51,901,400)
Balance (in shares) at Jun. 30, 2014		3,193,079	54,620,993
Series A Preferred Shares issued with Debenture - Series C	1,152,297	187	0	1,152,110
Series A Preferred Shares issued with Debenture - Series C (in shares)		187,000	0
Series A Preferred Shares issued for employee stock compensation	181,363	23	0	181,340
Series A Preferred Shares issued for employee stock compensation (in shares)		23,148	0
Shares issued for consulting and legal services	82,360		21	82,339
Shares issued for consulting and legal services (in shares)			20,880
Warrants issued to Scientific Advisory Board	52,130		0	52,130
Shares issued for consulting and legal services rendered on August 31, 2014 (in shares)			0
Common Shares issued in connection with exercise of warrants	6,743,297		1,927	6,741,370
Common Shares issued in connection with exercise of warrants (in shares)			1,926,656
Common shares issued for debenture interest	1,502,869		571	1,502,298
Common shares issued for debenture interest (in shares)			571,433
Series A Preferred Shares issued for consulting and legal services rendered	24,474	3		24,471
Series A Preferred Shares issued for consulting and legal services rendered on November 30, 2014 (in shares)		2,858
Shares issued for Directors fees	33,750		10	33,740
Shares issued for Directors fees (in shares)			10,453
Net loss	-1,280,461		0		-1,280,461
Balance at Mar. 31, 2015	$31,861,382	$3,407	$57,150	$84,982,686	($53,181,861)
Balance (in shares) at Mar. 31, 2015		3,406,085	57,150,415

Statements_of_Cash_Flows

Statements of Cash Flows (USD $)	9 Months Ended
Statements of Cash Flows (USD $)	Mar. 31, 2015	Mar. 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	($1,280,461)	($6,601,163)
Adjustments to reconcile net loss to net cash used in operating activities
Preferred shares issued as compensation	205,837	70,524
Common shares issued for services	116,110	96,751
Common shares issued for interest	1,502,869	2,605,716
Warrants granted to Scientific Advisory Board	52,130	167,954
Depreciation	153,996	151,902
Amortization	6,453	6,581
Change in fair value of derivative liability	-6,463,095	-1,585,067
Amortization of debt discount convertible debentures	860,454	419,305
Changes in operating assets and liabilities:
Prepaid expenses	-200,515	-740,515
Other current assets	150,000	0
Deferred interest payable	375,000	0
Accounts payable	-353,071	-8,256
Prepaid expenses/accounts payable - related parties	-115,555	35,469
Accrued expenses	33,215	2,736
NET CASH USED IN OPERATING ACTIVITIES	-4,956,633	-5,378,063
CASH FLOWS FROM INVESTING ACTIVITIES:
Collateral advance for affiliate	1,000,000	-1,000,000
Purchase of property and equipment	-5,564,152	-3,618,201
NET CASH USED IN INVESTING ACTIVITIES	-4,564,152	-4,618,201
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock and warrants in connection with private placements of common stock, net of issuance costs	0	28,602,740
Proceeds from exercise of warrants	6,743,297	735,626
NET CASH PROVIDED BY FINANCING ACTIVITIES	6,743,297	29,338,366
NET CHANGE IN CASH and CASH EQUIVALENTS	-2,777,488	19,342,102
Cash and Cash Equivalents at beginning of period	36,696,892	13,923,245
Cash and Cash Equivalents at end of period	33,919,404	33,265,347
SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION:
Interest paid	0	0
Income tax paid	0	0
NON CASH FINANCING AND INVESTING ACTIVITIES:
Series A Preferred stock issued as discount on debentures	1,152,297	0
Issuance of Series C Debenture for deposit received	5,000,000	0
Bifurccation of embedded derivative	1,879,428	0
Stock warrants granted to brokers	$0	$248,758

Organization_and_Nature_of_Bus

Organization and Nature of Business	9 Months Ended
Organization and Nature of Business	Mar. 31, 2015
Organization, Consolidation and Presentation Of Financial Statements [Abstract]
Nature of Operations [Text Block]	Note 1 - Organization and Nature of Business

	NanoViricides, Inc. (the “Company) was incorporated under the laws of the State of Colorado on July 25, 2000 as Edot-com.com, Inc. which was organized for the purpose of conducting internet retail sales. On April 1, 2005, Edot-com.com, Inc. was incorporated under the laws of the State of Nevada for the purpose of re-domiciling as a Nevada corporation. On May 12, 2005, the corporations were merged and Edot-com.com, Inc., the Nevada corporation, became the surviving entity.

	On June 1, 2005, Edot-com.com, Inc. (“ECMM”) acquired Nanoviricide, Inc., a privately owned Florida corporation (“NVI”), pursuant to an Agreement and Plan of Share Exchange (the “Exchange”). Nanoviricide, Inc. was incorporated under the laws of the State of Florida on May 12, 2005.

	Pursuant to the terms of the Exchange, ECMM acquired NVI in exchange for an aggregate of 80,000,000 newly issued shares of ECMM common stock resulting in an aggregate of 100,000,000 shares of ECMM common stock issued and outstanding. NVI then became a wholly-owned subsidiary of ECMM. The ECMM shares were issued to the NVI shareholders on a pro rata basis, on the basis of 4,000 shares of the Company’s common stock for each share of NVI common stock held by such NVI shareholder at the time of the Exchange.

	As a result of the Exchange transaction, the former NVI stockholders held approximately 80% of the voting capital stock of the Company immediately after the Exchange. For financial accounting purposes, this acquisition was a reverse acquisition of ECCM by NVI, under the purchase method of accounting, and was treated as a recapitalization with NVI as the acquirer. Accordingly, the financial statements have been prepared to give retroactive effect to May 12, 2005 (date of inception), of the reverse acquisition completed on June 1, 2005, and represent the operations of NVI.

	On June 28, 2005, NVI was merged into its parent ECMM and the separate corporate existence of NVI ceased. Effective on the same date, Edot-com.com, Inc. changed its name to NanoViricides, Inc. and its stock symbol to “NNVC”, respectively.

	NanoViricides, Inc. (the “Company”), is a nano-biopharmaceutical company whose business goals are to discover, develop and commercialize therapeutics to advance the care of patients suffering from life-threatening viral infections. We are a company with several drugs in various stages of early development. Our drugs are based on several patents, patent applications, provisional patent applications, and other proprietary intellectual property held by TheraCour Pharma, Inc. (“TheraCour”), an entity owned and controlled by a significant stockholder, to which we have the necessary exclusive, worldwide licenses in perpetuity. The first agreement we executed with TheraCour Pharma on September 1, 2005, gave us an exclusive, worldwide license for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Herpes Simplex Virus (HSV), Influenza and Asian Bird Flu Virus.

	On February 15, 2010, the Company executed an Additional License Agreement with TheraCour. Pursuant to the Additional License Agreement, the Company was granted exclusive, worldwide licenses, in perpetuity, for technologies, developed by TheraCour, for the development of drug candidates for the treatment of Dengue viruses, Ebola/Marburg viruses, Japanese Encephalitis, viruses causing viral Conjunctivitis (a disease of the eye) and Ocular Herpes. As consideration for obtaining these exclusive licenses, we agreed to pay a onetime licensing fee equal to 2,000,000 shares (adjusted for the 3.5 to 1 reverse split) of the Company’s Series A Convertible Preferred Stock (the “Series A Preferred Stock”). The Series A Preferred Stock is convertible, only upon sale or merger of the Company, or the sale of or license of substantially all of the Company’s intellectual property, into shares of the Company’s common stock at the rate of 3.5 shares of common stock for each share of Series A Preferred Stock. The Series A Preferred Stock has a preferred voting preference at the rate of nine votes per share. The Preferred Series A do not contain any rights to dividends, have no liquidation preference, and are not to be amended without the holder’s approval. The 2,000,000 shares were valued at the par value of $2,000.

Restatement_of_Previously_Issu

Restatement of Previously Issued Financial Statements	9 Months Ended
Restatement of Previously Issued Financial Statements	Mar. 31, 2015
Accounting Changes and Error Corrections [Abstract]
Accounting Changes and Error Corrections [Text Block]	Note 2- Restatement of Previously Issued Financial Statements

	In connection with the preparation of our unaudited financial statements for the quarter ended December 31, 2014, we determined that in preparing our audited financial statements for the year ended June 30, 2014, we inadvertently overlooked the anti-dilution provisions in certain warrants issued in connection with the Company’s private placements of securities. Specifically, the warrants issued contained certain anti-dilution ratchet provisions that provided for an adjustment to the exercise price of the warrants if the Company issued any stock equivalent securities at a lower price in the future while the warrants were still outstanding. Adjustments to settlement amounts by future equity offerings or contractual terms of other equity linked financial instruments issued in a subsequent period are not inputs to the fair value of a fixed-for-fixed option on equity shares. Accordingly, the warrants are not considered indexed to its own stock and thus must be accounted for as derivative liabilities which require initial measurement at fair value and adjustment to fair value in subsequent periods . The Company determined that the error caused a material understatement of its derivative liability at June 30, 2014. As a result of this error, we filed the Form 10-K/A to restate our audited financial statements for the year ended June 30, 2014, on February 23, 2015 and the Form 10-Q/A to restate the unaudited financial statements for the three month periods ended September 30, 2014 and 2013. Form 10-Q for the three and six month periods ended December 31, 2014 and 2013 has also been restated for the three and six month periods ended December 31, 2013 to reflect the correction of the aforementioned error included in those periods.

	The financial statements for the three and nine month periods ended March 31, 2014, include restatements to reflect the aforementioned omission of the derivative liabilities arising from the anti-dilution provisions in the aforesaid warrants issued in conjunction with the Company’s private placement of securities included in those periods. For the three and nine months ended March 31, 2014 the net adjustment to net income/loss recognized by the Company is $1,618,264 and $1,658,409 respectively. The net adjustment resulting from the recognition of the warrant derivative liability is an increase of $4,082,131 to derivative liability and a corresponding reduction in additional paid in capital of $4,082,131.

	The impact of the above adjustment to the line items in our unaudited financial statements as of March 31, 2014 and for the three and nine months ended March 31, 2014 are summarized in the tables below:

	Balance Sheet Data

		March 31, 2014		Net Adjustments		March 31, 2014
		(Unaudited)				(Unaudited)
		As Originally Reported				As Restated

	LONG TERM LIABILITIES:
	Debentures payable - Series B	$	3,887,378	$	-	$	3,887,378
	Derivative liability -Series B		3,824,986		-		3,824,986
	Derivative liability -warrants		-		4,082,131		4,082,131
	Total Long Term Liabilities		7,712,364		4,082,131		11,794,495

	Total Liabilities		8,920,548		4,082,131		13,002,679

	STOCKHOLDERS' EQUITY:
	Additional paid-in capital		78,531,194		-5,740,540		72,790,654
	Accumulated deficit		-46,559,356		1,658,409		-44,900,947

	Total Stockholders' Equity	$	32,029,392	$	-4,082,131	$	27,947,261

	Statements of Operations
	(Unaudited)

		For the Three Months				For the Three Months		For the Nine Months				For the Nine Months
		Ended				Ended		Ended				Ended
		March 31, 2014		Net Adjustments		March 31,2014		March 31, 2014		Net Adjustments		March 31,2014
		As Originally Reported				As Restated		As Originally Reported				As Restated
	OPERATING EXPENSES
	Research and development	$	625,737	$	-	$	625,737	$	2,930,436	$	-	$	2,930,436
	Refund credit research and development costs		-		-				-		-
	General and administrative		607,628		-		607,628		1,943,123		-		1,943,123

	Total operating expenses		1,233,365		-		1,233,365		4,873,559		-		4,873,559

	LOSS FROM OPERATIONS		-1,233,365		-		-1,233,365		-4,873,559		-		-4,873,559

	OTHER INCOME (EXPENSE):
	Interest income		54,789		-		54,789		78,850		-		78,850
	Interest expense		-2,725,716		-		-2,725,716		-2,972,216		-		-2,972,216
	Discount on convertible debentures		-143,051		-		-143,051		-419,305		-		-419,305
	Change in fair market value of derivatives		3,752,933		1,618,264		5,371.20		-73,342		1,658,409		1,585,067

	Other income (expense), net		938,955		1,618,264		2,557,219		-3,386,013		1,658,409		-1,727,604

	(LOSS ) INCOME BEFORE INCOME TAX PROVISION		-294,410		1,618,264		1,323,854		-8,259,572		1,658,409		-6,601,163

	INCOME TAX PROVISION		-		-		-		-		-

	NET (LOSS) INCOME	$	-294,410	$	1,618,264	$	1,323,854	$	-8,259,572	$	1,658,409	$	-6,601,163

	NET (LOSS) INCOME PER COMMON SHARE
	- Basic	$	-0.01			$	0.02	$	-0.16				-0.13
	- Diluted	$	-0.01			$	-0.02	$	-0.16			$	-0.13

	Weighted average common shares outstanding
	- Basic		53,318,736				53,318,736		50,307,984				50,307,984
- Diluted		53,318,736				55,033,023		50,307,984				50,307,984

Summary_of_Significant_Account

Summary of Significant Accounting Policies	9 Months Ended
Summary of Significant Accounting Policies	Mar. 31, 2015
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	Note 3 - Summary of Significant Accounting Policies

	Basis of Presentation – Interim Financial Information

	The accompanying unaudited interim financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission for Interim Reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) which are, in the opinion of management, considered necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. The accompanying financial statements and the information included under the heading “Management’s Discussion and Analysis or Plan of Operation” should be read in conjunction with our Company’s audited financial statements and related notes included in our Company’s form 10-K/A for the fiscal year ended June 30, 2014 filed with the SEC on February 23, 2015.

	Reclassifications

	Certain accounts in the June 30, 2014 financial statements have been reclassified to conform to the current period presentation.

	For a summary of significant accounting policies, see the Company’s Annual Report on Form 10-K/A for the fiscal year ended June 30, 2014 filed on February 23, 2015.

	Net Income (Loss) per Common Share

	Net income (loss) per common share is computed pursuant to section 260-10-45 of the FASB Accounting Standards Codification. Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants, convertible preferred stock, and convertible debentures.

	The following table shows the number of potentially outstanding dilutive common shares excluded from the diluted net income (loss) per common share calculation as they were anti-dilutive:

			Potentially Outstanding Dilutive Common Shares
			For the			For the
			Nine Months			Nine Months
			Ended			Ended
			31-Mar-15			31-Mar-14

	Stock options			535,715			535,715

	Warrants			5,959,527			8,870,065

	Total potentially outstanding dilutive common shares			6,495,242			9,405,780

	In addition, the Company has issued Convertible Debentures, to investors. A portion of the interest required to be paid on the debentures had been paid in shares of the Company’s $0.001 par value common stock (“ Interest Shares”) according to the terms of the Debenture. No additional Interest Shares are required to be issued under the terms of the debenture. The Company will need to issue 571,428 warrants on January 15, 2016 relating to the additional interest to be paid on the Series B debentures. Coupon interest payable quarterly related to the Series B Debentures is payable in cash or shares of Common Stock at the average of the open and close value on the date such interest payment is due at the option of the Holder. The Holders have elected to receive coupon interest in cash.

	At March 31, 2015, the estimated number of potentially dilutive shares of the Company’s common stock into which the Series B debentures can be converted based upon the conversion price of $3.50 is 1,714,286. At March 31, 2015 the number of potential dilutive shares of the Company’s common stock into which the Series C debentures can be converted based upon the conversion provisions contained in the debenture is 952,381.

	The Company has also issued 3,406,085 of $0.001 par value Preferred A shares to investors and others as of March 31, 2015. Only in the event of a “change of control” of the Company, each Series A preferred share is convertible to 3.5 shares of its new common stock. A “Change of Control” is defined as an event in which the Company’s shareholders become 60% or less owners of a new entity as a result of a change of ownership, merger or acquisition. In the absence of a Change of Control event, the Series A stock is not convertible into Common Stock, and does not carry any dividend rights or any other financial effects. At March 31, 2015, the estimated number of potentially dilutive shares of the Company’s common stock into which these Series A Preferred shares can be converted into is 11,921,298, and is not included in diluted earnings per share since the shares are contingently convertible only upon a Change of Control.

	Pursuant to the Redemption provisions of the Series C Debentures, the Company, at its sole option, shall have the right, but not the obligation, to repurchase the Debenture at any time prior to the Maturity Date (the “Redemption”). If the Company intends to repurchase the Debenture, and if the closing bid price of the Common Stock is greater than $5.25 on the Redemption Date, unless the Holder, on or prior to the Redemption Date, elects to receive the “Redemption Payment”, as that term is defined herein, the Company shall pay to the Holder: (i) 952,381 shares of Common Stock in consideration of the exchange of the principal amount of the Debenture; and (ii) any and all accrued coupon interest. If on or prior to the Redemption Date, the Holder elects to receive the Redemption Payment, or the closing bid price of the Common Stock is less than $5.25, the Company shall issue to the Holder: (i) the principal amount of the Debenture; (ii) any accrued coupon interest; (iii) additional interest of 7% per annum for the period from the date of issuance of the Debenture to the Redemption Date; and (iv) warrants to purchase 619,048 shares of Common Stock which shall expire in three years from the date of issuance at an exercise price of $6.05 per share of Common Stock (the “Redemption Warrants”, and collectively with (i) – (iii), the “Redemption Payment”). The Company shall use its best efforts to register the shares underlying the Redemption Warrants under a “shelf” registration statement, provided same is available to the Company, in accordance with the provisions of the Securities Act.

	The following represents a reconciliation of the numerators and denominators of the basic and diluted per share calculations for income from continuing operations:

			For the three months ended						For the nine months ended
			March 31,			March 31,			March 31,			March 31,
			2015			2014			2015			2014
	Calculation of basic loss per share of common stock:

	Net (loss) income attributable to common stockholders		$	-251,018		$	1,323,854		$	-1,280,462		$	-6,601,163

	Denominator for basic weighted average shares of common stock			56,941,122			53,318,736			56,356,105			50,307,984

	Basic (loss) income per share of common stock		$	0		$	0.02		$	-0.02		$	-0.13

	Calculation of diluted loss per share of common stock:

	Net (loss) income attributable to common stockholders		$	-251,018		$	1,323,854		$	-1,280,462		$	-6,601,163

	Add: Income impact of assumed conversion of Debentures			-696,103			-2,502,430			-2,740,562			-

	Net (loss) income attributable to common stockholders plus assumed conversions		$	-947,121		$	-1,178,576		$	-4,021,024		$	-6,601,163

	Denominator for basic weighted average shares of common stock			56,941,122			53,318,737			56,356,105			50,307,984

	Incremental shares from assumed conversions of Debentures payable			2,666,667			1,714,286			2,666,667			-

	Denominator for diluted weighted average shares of common stock			59,607,788			55,033,023			59,022,772			50,307,984

Diluted (loss) income per share of common stock		$	-0.02		$	-0.02		$	-0.07		$	-0.13

Series B Debentures were excluded from the loss per share calculation for the three and nine months ended March 31, 2014 because the impact is anti-dilutive.

Recently Issued Accounting Pronouncements

In June 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-12, "Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period." This ASU requires a reporting entity to treat a performance target that affects vesting and that could be achieved after the requisite service period as a performance condition, and apply existing guidance under the Stock Compensation Topic of the ASC as it relates to awards with performance conditions that affect vesting to account for such awards. The provisions of this ASU are effective for interim and annual periods beginning after December 31, 2015. The Company is currently evaluating the impact of this ASU.

In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”). ASU 2014-15 is intended to define management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. Specifically, ASU 2014-15 provides a definition of the term substantial doubt and requires an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). It also requires certain disclosures when substantial doubt is alleviated as a result of consideration of management’s plans and requires an express statement and other disclosures when substantial doubt is not alleviated. The new standard will be effective for reporting periods beginning after December 15, 2016, with early adoption permitted. Management is currently evaluating the impact of the adoption of ASU 2014-14 on the Company’s financial statements and disclosures.

In April 2015, the FASB issued ASU 2015-03, Interest - Imputation of Interest (Subtopic 835-30), “Simplifying the Presentation of Debt Issuance Costs,” which requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. This ASU requires retrospective adoption and will be effective for fiscal years beginning after December 15, 2015 and for interim periods within those fiscal years. We expect the adoption of this guidance will not have a material impact on our financial statements.

Financial_Condition

Financial Condition	9 Months Ended
Financial Condition	Mar. 31, 2015
Financial Conditons Disclosure [Abstract]
Financial Conditons Disclosure [Text Block]	Note 4 - Financial Condition

	The Company’s financial statements for the interim period ended March 31, 2015 have been prepared on a going concern basis, which contemplates the realization of assets and settlement of liabilities and commitments in the normal course of business. The Company has an accumulated deficit at March 31, 2015 of ($53,181,861). In addition, the Company has not generated any revenues and no revenues are anticipated in the short-term. Since May 2005, the Company has been engaged exclusively in research and development activities focused on developing targeted antiviral drugs. The Company has not yet commenced any product commercialization. Such losses are expected to continue for the foreseeable future and until such time, if ever, as the Company is able to attain sales levels sufficient to support its operations. There can be no assurance that the Company will achieve or maintain profitability in the future. As of March 31, 2015 the Company had cash and cash equivalents of $33,919,404. The Company has sufficient capital to continue its business, at least, through March 31, 2017, at the current rate of expenditure.

	While the Company continues to incur significant operating losses with significant capital requirements, the Company has been able to finance its business through sale of its securities. The Company may require additional capital to finance planned and currently unplanned capital costs and additional staffing requirements during the next 24 months. The Company has in the past adjusted its priorities and goals in line with the cash on hand and capital availability. The Company believes it can adjust its priorities of drug development and its plan of operations as necessary, if it is unable to raise additional funds.

Related_Party_Transactions

Related Party Transactions	9 Months Ended
Related Party Transactions	Mar. 31, 2015
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	Note 5 - Related Party Transactions

	Related Parties

	Related parties with whom the Company had transactions are:

	Related Parties	Relationship

	Anil R. Diwan	Chairman, President, significant stockholder and director

	Eugene Seymour	CEO, significant stockholder, director

	TheraCour Pharma, Inc.	An entity owned and controlled by significant stockholder

	Inno-Haven, LLC	An entity owned and controlled by significant stockholder

	Milton Boniuk, MD	Director and significant stockholder


	Property and Equipment

		For the nine months ended
		March 31, 2015
	During the reporting period, the Company acquired 1 Controls Drive Shelton Ct from Inno-Haven, LLC	$	4,222,549

	During the reporting period, Inno-Haven, LLC, acquired property and equipment on behalf of the Company from third party vendors and sold such property and equipment, at cost, to the Company	$	-

	During the reporting period, TheraCour Pharma, Inc. acquired property and equipment on behalf of the Company from third party vendors and sold such property and equipment, at cost, to the Company	$	222,582

	Prepaid Expense (Accounts Payable) Related Party

		As of		As of
		March 31, 2015		June 30, 2014
	Pursuant to an Exclusive License Agreement and an Additional License Agreement we entered into with TheraCour Pharma, Inc., (TheraCour), the Company was granted exclusive licenses in perpetuity for technologies developed by TheraCour for the virus types: HIV, HCV, Herpes, Asian (bird) flu, Influenza and rabies, and others. In consideration for obtaining these exclusive licenses, we agreed: (1) that TheraCour can charge its costs (direct and indirect) plus no more than 30% of direct costs as a Development Fee and such development fees shall be due and payable in periodic installments as billed. (2) we will pay $25,000 per month for usage of lab supplies and chemicals from existing stock held by TheraCour, (3) we will pay $2,000 per month or actual costs, whichever is higher for other general and administrative expenses incurred by TheraCour on our behalf. Prepaid Expense (Accounts payable) due TheraCour Pharma Inc. (including a two (2) month security advance):	$	66,100	$	-49,455

	Research and Development Costs Paid to Related Parties

		For the three months ended				For the nine months ended
		March 31,		March 31,		March 31,		March 31,
		2015		2014		2015		2014

	Development fees and other costs charged by and paid to TheraCour Pharma, Inc. pursuant to exclusive License Agreements between TheraCour and the Company for the development of the Company’s drug pipeline. No royalties are due TheraCour from the Company at March 31, 2015 and 2014	$	398,407	$	391,628	$	1,688,547	$	1,315,753

	Long Term Debenture Payable to a Director

		March 31, 2015		June 30, 2014

	Series B Convertible Debentures - Milton Boniuk	$	4,000,000	$	4,000,000

	Series C Convertible Debentures: - Milton Boniuk		5,000,000		-

	Total Long Term Debentures Payable to a Director	$	9,000,000	$	4,000,000

Property_and_Equipment

Property and Equipment	9 Months Ended
Property and Equipment	Mar. 31, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	Note 6 - Property and Equipment

	Property and equipment, stated at cost, less accumulated depreciation consisted of the following:

		March 31,		June 30,
		2015		2014

	Building GMP Facility	$	8,376,336	$	3,099,780

	Office Equipment		30,048		30,048

	Furniture and Fixtures		1,400		1,400

	Lab Equipment		3,893,110		3,605,514

	Total Property and Equipment		12,300,894		6,736,742

	Less Accumulated Depreciation		-1,393,982		-1,239,986
	Property and Equipment, Net	$	10,906,912	$	5,496,756

	Depreciation expense for the nine months ended March 31, 2015 and 2014 was $153,996 and $151,902, respectively.

	On December 31, 2014, the Company entered into and consummated an Agreement for the Purchase and Sale of a cGMP-compliant pilot manufacturing and lab facility at 1 Controls Drive, Shelton, Connecticut. The purchase price of the facility was comprised solely of the repayment of the direct costs of the seller, Inno-Haven, LLC (“Inno-Haven”), an entity owned and controlled by a significant stockholder, incurred in acquiring and renovating the property and the facility plus Inno-Haven’s closing costs in connection with the sale. The purchase price consisted of the repayment of Inno-Haven’s acquisition and renovation expenses of $4,222,549 and closing costs of $81,230.

Trademark_and_Patents

Trademark and Patents	9 Months Ended
	Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets Disclosure [Text Block]	Note 7 - Trademark and Patents

	Trademark and patents, stated at cost, less accumulated amortization consisted of the following:

		March 31,		June 30,
		2015		2014

	Trademarks and Patents	$	458,954	$	458,954
	Less Accumulated Amortization		-57,149		-50,696
	Trademarks and Patents, Net	$	401,805	$	408,258

	Amortization expense amounted to $6,453 and $6,581 for the nine months ended March 31, 2015, and 2014, respectively.

Convertible_Debentures

Convertible Debentures	9 Months Ended
Convertible Debentures	Mar. 31, 2015
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	Note 8 – Convertible Debentures

	On February 1, 2013, the Company raised gross proceeds of $6,000,000 which includes $4,000,000 from a family investment office and a charitable foundation controlled by Dr. Milton Boniuk, a member of the Company’s board of directors, through the issuance of our Series B Debentures. The investors purchased unsecured convertible debentures with a 4-year term. The debentures bear an interest rate of 8% p.a. payable quarterly in cash or the Holder at its option may elect to receive such coupon interest payment in shares of common stock and calculated on the issuance, average of the open and close value on the date such interest payment is due. Additional interest is payable in restricted common stock of 571,429 shares at issuance, January 15, 2014, and 2015, and additional interest of 571,429 warrants to be issued on January 15, 2016. The warrants are exercisable at $3.50 per warrant and will be valid for 3 years after issuance. The investors can convert the principal and any accrued interest into common stock at a fixed price of $3.50 per share. The Company can prepay the debentures, in which case the base interest rate shall increase by a 7% prepayment penalty. The Company agreed to use its best efforts to register the interest shares and the shares issuable from the interest warrants under a “shelf” registration statement provided same is available, in accordance with the provisions of the Securities Act.

	The following table presents the balance of the Debenture payable – Series B, net of discount at March 31, 2015 and June 30, 2014. The debt discount is being accreted to interest expense over the term of the debenture:

			March 31,		June 30,
			2015		2014


	Proceeds		$	6,000,000	$	6,000,000
	Debt discount for bifurcated derivative			-2,735,310		-2,735,310
				3,264,690		3,264,690

	Amortization of debt discount			1,261,039		772,878

	Debenture payable - Series B, net		$	4,525,729	$	4,037,568

	The debenture contains embedded derivatives which are not clearly and closely related to the host instrument. The embedded derivatives are bifurcated from the host debt instrument and treated as a liability.

	The single compound embedded derivative features valued include the:

		1	Principal conversation feature at maturity based on fixed conversion price subject to standard adjustments.

		2	Redemption additional interest and Redemption Warrants offering.

		3	Additional Interest Shares and Interest Warrants.

	For the three and nine months period ended March 31, 2015 the Company recognized amortization of this discount as an additional interest charge to “Discount on convertible debentures” in the amounts of $166,543 and $488,161 respectively.

	The Company used a lattice model that values the compound embedded derivatives of the Series B Convertible Debenture based on a probability weighted discounted cash flow model at March 31, 2015.

	The following assumptions were used for the valuation of the compound embedded derivative at March 31, 2015:

		·	The balance of the Series C Convertible Debenture as of issuance and March 31, 2015 is $6,000,000;

		·	The underlying stock price was used as the fair value of the common stock; The stock price decreased to $2.25 at March 31, 2015 which decreased the warrant value with the $3.50 exercise price (further out to in the money);

		·	The projected annual volatility was based on the Company historical volatility:

	1 year
	12/31/2014 75%
	3/31/2015 67%

		·	An event of default would occur 0% of the time, increasing 1.00% per month to a maximum of 10%;

		·	The Company would redeem the debentures projected initially at 0% of the time and increase monthly by 1.0% to a maximum of 5.0% (from alternative financing being available for a Redemption event to occur);

		·	The Holder would automatically convert the interest if the Company was not in default and its shares value would equivalent to the cash value;

		·	The Holder would automatically convert the debenture at maturity if the registration was effective and the Company was not in default.

		·	The Weighted Cost of Capital discount rate (based on the Market Value of the transaction at issuance) adjusted for changes in the risk free rate is 21.86%.

		·	Even through the shares are restricted the underlying assumption is that any restriction on resale will be removed either through registration or the passage of time at the time of issuance.

	The fair value of the compound embedded derivatives of the Series B Convertible Debenture at March 31,2015 was $930,940.

	On July 2, 2014 (the “Closing Date”), the Company accepted a subscription in the amount of $5,000,000 for a 10% Coupon Series C Convertible Debenture (the “Debenture”) from Dr. Milton Boniuk, a member of the Company’s Board of Directors (the “Holder”). The $5,000,000 funding of the Debenture had been received by the Company prior to June 30, 2014, the year-end reporting period and the Company has reported the said Debenture in the financial statements at June 30, 2014 under long term liabilities. The Debenture is due on June 30, 2018 (the “Maturity Date”) and is convertible, at the sole option of the Holder, into restricted shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”) at the conversion price of $5.25 per share of Common Stock. The Debenture bears interest at the coupon rate of ten percent (10%) per annum, computed on an annual basis of a 365 day year, payable in quarterly installments on March 31, June 30, September 30 and December 31 of each calendar year until the Maturity Date. The Holder at its option may choose to receive such coupon interest payment in shares of Common Stock calculated on the average of the open and close value on the date such interest payment is due. To date, the Holder has elected to take such coupon interest in cash. The Company has the right, but not the obligation, to repay the Debenture prior to the Maturity Date (the “Redemption Payment”). If the closing bid price of the Common Stock is in excess of $5.25 when the Company notifies the Holder it has elected to prepay the Debenture (the “Redemption Date”), the Company must redeem the Debenture by delivering to the Holder 952,381 shares of Common Stock and any unpaid coupon interest in lieu of a cash Redemption Payment. If the Holder elects to receive the Redemption Payment in cash, or if the closing bid price of the Common Stock is less than $5.25, the Company shall pay to the Holder a Redemption Payment in cash equal to the principal amount of the Debenture, plus any accrued coupon interest, plus additional interest of 7% per annum for the period from the Closing Date to the Redemption Date and warrants to purchase 619,048 shares of Common Stock which shall expire in three years from the date of issuance at the exercise price of $6.05 per share of Common Stock. The Company cannot conclude that it has sufficient authorized and unissued shares to settle the contract after considering all other commitments that may require the issuance of stock during the maximum period the derivative instrument could remain outstanding. This is due to the fact that the interest payments are payable in stock of the Company, at the option of the Holder, based on the current market price of the common stock on the date such payments are due. Therefore, the number of shares due as interest payments is essentially indeterminate and the Company cannot conclude that it has sufficient authorized and unissued shares to settle the conversion feature. Accordingly, the Company bifurcated the embedded features from the host contract and recorded them as a derivative liability at fair value. A debt discount was recognized for a derivative liability associated with embedded features bifurcated from the Series C Convertible Debenture.

	On July 2, 2014, in conjunction with the issuance of the Company’s Series C Convertible Debentures, the Company issued 187,000 shares of its Series A Convertible Preferred stock (the “Series A”) to Dr. Milton Boniuk, pursuant to the terms of the Debenture. Proceeds received in a financing transaction are allocated to the instruments issued prior to evaluating hybrid contracts for bifurcation of embedded derivatives. Since the Series A Convertible Preferred Stock is classified as equity, the proceeds allocated to the Preferred Stock are recorded at relative fair value . The fair value of the Series A was $1,645,606 at issuance and the relative fair value was calculated as $1,152,297. The remaining amount of the proceeds was allocated to the Debenture and a debt discount of $1,152,297 was recorded to offset the amount of the proceeds allocated to the Series A. Then, the embedded derivative was bifurcated at its fair value of $1,879,428 with the remaining balance allocated to the host instrument (Debenture). The total debt discount will be amortized over the term of the Debenture using the effective interest method. For the three and nine months period ended March 31, 2015 the Company recognized amortization of this discount as an additional interest charge to “Discount on convertible debentures” in the amounts of $130,733 and $372,293 respectively.

	The following represents the balance of the Debenture payable – Series C, net of discount at March 31, 2015:

Proceeds		$	5,000,000
Debt discount
Series A Preferred			-1,152,297
Embedded derivative			-1,879,428
			1,968,275

Amortization of debt discount for the nine months ended March 31, 2015			372,293

Balance at March 31, 2015		$	2,340,568

The Company used a lattice model that values the compound embedded derivatives of the Series C Convertible Debenture based on a probability weighted discounted cash flow model at March 31, 2015.

The following assumptions were used for the valuation of the compound embedded derivative at March 31, 2015:

	·	The balance of the Series C Convertible Debenture as of March 31, 2015 is $5,000,000;

	·	The underlying stock price was used as the fair value of the common stock; The stock price decreased to $2.25 at March 31, 2015 which decreased the warrant value with the $6.05 exercise price (further out to in the money);

	·	The projected annual volatility was based on the Company historical volatility:

1 year
12/31/2014 75%
3/31/2015 67%

	·	An event of default would occur 0% of the time, increasing 1.00% per month to a maximum of 10%;

	·	The Company would redeem the debentures projected initially at 0% of the time and increase monthly by 1.0% to a maximum of 5.0% (from alternative financing being available for a Redemption event to occur);

	·	The Holder would automatically convert the interest if the Company was not in default and its shares value was equivalent to the cash value;

	·	The Holder would automatically convert the debenture at maturity if the registration was effective and the Company was not in default.

	·	The weighted cost of capital discount rate (based on the market value of the transaction at issuance) adjusted for changes in the risk free rate is 21.86%.

	·	Even through the shares are restricted the underlying assumption is that any restriction on resale will be removed either through registration or the passage of time at the time of issuance.

The fair value of the compound embedded derivatives of the Series C Convertible Debenture at March 31, 2015 was $809,305.

Equity_Transactions

Equity Transactions	9 Months Ended
	Mar. 31, 2015
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	Note 9 - Equity Transactions

	On July 17, 2014 the Company filed a registration statement on Form S-3 (the “Form S-3”) registering an aggregate of 3,071,986 shares of common stock underlying warrants previously issued by the Company in various private placement offerings between 2005 and September 2009, (“Old Warrants”) as described more fully in the Form S-3 (the “Registered Warrants”). The Form S-3 was declared effective by the Securities and Exchange Commission on August 1, 2014. Holders of the Old Warrants were required to submit Notice of Exercise by August 15, 2014, or their warrants would expire. The Company received Notices to Exercise Warrants and the exercise price to purchase an aggregate of 1,926,656 shares of the Company’s common stock at the exercise price of $3.50 per share for an aggregate purchase price of $6,743,297.

	On February 1, 2015 the Company’s Board of Directors authorized the issuance of 571,433 shares of the Company’s $0.001 par value common stock as annual interest payable to holders of the Company’s Series B Debentures. The Company recorded interest expense of $1,502,869 for the three month period ended March 31, 2015 calculated using the fair market value of the Company’s common stock on the date issued.

	Unregistered Securities

	As discussed in Note 8, on July 2, 2014, in conjunction with the issuance of the Company’s Series C Convertible Debentures, the Company issued 187,000 Shares of its Series A Convertible Preferred stock to Dr. Milton Boniuk, pursuant to the terms of the Debenture. The Company allocated the proceeds received between the Debenture and the Preferred Stock on a relative fair value basis. The amount allocated to the Preferred stock was $1,152,297.

	For the nine months ended March 31, 2015, the Scientific Advisory Board was granted fully vested warrants to purchase 51,444 shares of common stock at exercise prices between $3.62- $5.04 per share expiring in the fiscal year ending June 30, 2018. These warrants were valued at $52,130 and recorded as consulting expense.

	For the nine months ended March 31, 2015, the Company estimated the fair value of the warrants granted quarterly to the Scientific Advisory Board on the date of grant using the Black-Scholes Option-Pricing Model with the following weighted-average assumptions:

	Expected life (year)		4

	Expected volatility		37.44% -45.84	%

	Expected annual rate of quarterly dividends		0	%

	Risk-free rate(s)		1.20 - 1.67	%

	For the nine months ended March 31, 2015, the Company’s Board of Directors authorized the issuance of 23,148 shares of its Series A Convertible Preferred stock for employee compensation. The Company recorded an expense of $181,363.

	For the nine months ended March 31, 2015, the Company’s Board of Directors authorized the issuance of 2,858 shares of its Series A Convertible Preferred Stock which are fully vested for consulting services. The Company recorded an expense of $24,474.

	For the nine months ended March 31, 2015, the Company’s Board of Directors authorized the issuance of 20,881 shares of its common stock which are fully vested with a restrictive legend for consulting services. The Company recorded an expense of $82,360 which is the fair value at date of issuance.

	For the nine months ended March 31, 2015, the Company’s Board of Directors authorized the issuance of 10,453 shares of its common stock which are fully vested with a restrictive legend for Director services. The Company recorded an expense of $33,750 which is the fair value at date of issuance.

	There is currently no market for the shares of Series A Preferred Stock and they can only be converted into shares of common stock upon a Change of Control of the Company as more fully described in the Certificate of Designation. The Company, therefore, estimated the fair value of the Preferred A shares granted to various employees and others on the date of grant. The Preferred Series A shares fair value is based on the greater of i) the converted value to common at a ratio of 1:3.5; ii) the value of the voting rights since the holder would lose the voting rights upon conversion. The conversion of the shares is triggered by a Change of Control. The valuations of the Series A Preferred Stock at March 31, 2015 used the following inputs:

	a.	The common stock price was in the range $2.72 to $2.29;

	b.	The calculated weighted average number of shares of common stock in the period;

	c.	A 5.36% premium over the common shares for the voting preferences;

	d.	The calculated weighted average number of total voting shares and the monthly shares representing voting rights of 4.896% to 5.046% of the total;

	e.	The conversion value is based on an assumption for calculation purposes only of a Change of Control in 4 years from March 1, 2013 and a remaining restricted term of 2.08 to 1.92 years;

	f.	32.61% to 31.42% restricted stock discount (based on a restricted stock analysis and call-put analysis curve: 78.63% to 69.38% volatility, 0.674% to 0.47% risk free rate) applied to the converted common.

Stock_Options_and_Warrants

Stock Options and Warrants	9 Months Ended
Stock Options and Warrants	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	Note 10 – Stock Options and Warrants

	The following table presents the activity of stock options issued for the nine months ended March 31, 2015 as follows:

	Stock Options	Number of		Weighted		Weighted		Aggregate
		Shares		Average		Average		Intrinsic
				Exercise Price		Remaining		Value ($)
				per share ($)		Contractual
						Term (years)
	Outstanding at June 30, 2014		535,715	$	0.35		1.23	$	2,094,643
	Granted		-		-		-		-
	Exercised		-		-		-		-
	Expired		-		-		-		-
	Canceled		-		-		-		-
	Outstanding at March 31,2015		535,715	$	0.35		0.48.	$	996,424

	As of March 31, 2015 there was no unrecognized compensation cost.

	Stock Warrants	Number of		Weighted		Weighted		Aggregate
		Shares		Average		Average		Intrinsic Value
				Exercise		Remaining		($)
				Price		Contractual Term
				per share		(years)
				($)
	Outstanding and exercisable at June 30, 2014		8,894,355	$	5.01		2.78	$	2,278,458

	Granted		51,444		4.18		-		-
	Exercised		1,926,656		3.5		-		-
	Expired		1,059,616		-		-		-
	Canceled		-		-		-		-
	Outstanding and exercisable at March 31, 2015		5,959,527	$	5.15		3.34	$	19,004

	Of the above warrants, 277,149 expire in fiscal year ending June 30, 2015; and 68,571 expire in fiscal year ending June 30, 2016; 68,571 expire in fiscal year ending June 30, 2017; 68,570 in fiscal year ending June 30,2018; 5,476,666 in fiscal year ending June 30, 2019.

Fair_Value_Measurement

Fair Value Measurement	9 Months Ended
Fair Value Measurement	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	Note 11 – Fair Value Measurement

	Fair value measurements

	Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value for applicable assets and liabilities, we consider the principal or most advantageous market in which we would transact and we consider assumptions market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. This guidance also establishes a fair value hierarchy to prioritize inputs used in measuring fair value as follows:

	⋅	Level 1: Observable inputs such as quoted prices in active markets;

	⋅	Level 2: Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and

	⋅	Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

	At March 31, 2015 and June 30, 2014, the fair value of derivative liabilities is estimated using a lattice model that is based on the individual characteristics of our warrants, preferred and common stock, the derivative liability on the valuation date as well as assumptions for volatility, remaining expected life, risk-free interest rate and, in some cases, credit spread. The derivative liabilities are the only Level 3 fair value measures.

	At March 31, 2015 and June 30, 2014, the estimated fair values of the liabilities measured on a recurring basis are as follows:

			Fair Value Measurements at
			March 31, 2015:

			(Level 1)		(Level 2)		(Level 3)

	Derivative liability – Series B debentures		$	-		-	$	930,940
	Derivative liability – Series C debentures			-		-		809,305
	Derivative liability – warrants			-		-		4,611,472
	Total derivatives		$	-	$	-	$	6,351,717

			Fair Value Measurements at
			June 30, 2014 (Restated):

			(Level 1)		(Level 2)		(Level 3)

	Derivative liability – Series B debentures		$	-	$	-		5,699,703
	Derivative liability - warrants			-		-		5,235,682
	Total derivatives		$	-	$	-	$	10,935,385

	The following tables present the activity for liabilities measured at estimated fair value using unobservable inputs for the nine months ended March 31, 2015:

			Fair Value Measurement
			Using Significant
			Unobservable Inputs
			Derivative liability – Series B		Derivative liability – Series C		Derivative liability - warrant

	Beginning balance at July 1, 2014		$	5,699,703	$	-	$	5,235,682
	Additions during the year			-		1,879,428		-
	Change in fair value			-4,768,763		-1,070,123		-624,210
	Transfer in and/or out of Level 3			-		-		-
	Ending balance at March 31, 2015		$	930,940	$	809,305	$	4,611,472

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	Note 12 - Commitments and Contingencies

	Operating Lease

	The Company maintains facilities located at 135 Wood Street, West Haven, Connecticut, that includes approximately 7,000 square feet of office and laboratory space at a base monthly rent of $8,695. The term of lease expired on February 28, 2011 and is now on a month-by-month basis.

	Total rent expense at 135 Wood Street, West Haven, Connecticut amounted to $78,255 and $78,255 for the nine months ended March 31, 2015 and 2014, respectively.

	Legal Proceedings

	There are no pending legal proceedings against the Company to the best of the Company’s knowledge as of the date hereof and to the Company’s knowledge, no action, suit or proceeding has been threatened against the Company.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	9 Months Ended
Summary of Significant Accounting Policies (Policies)	Mar. 31, 2015
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation – Interim Financial Information

	The accompanying unaudited interim financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission for Interim Reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) which are, in the opinion of management, considered necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. The accompanying financial statements and the information included under the heading “Management’s Discussion and Analysis or Plan of Operation” should be read in conjunction with our Company’s audited financial statements and related notes included in our Company’s form 10-K/A for the fiscal year ended June 30, 2014 filed with the SEC on February 23, 2015.

Reclassification, Policy [Policy Text Block]	Reclassifications

	Certain accounts in the June 30, 2014 financial statements have been reclassified to conform to the current period presentation.

	For a summary of significant accounting policies, see the Company’s Annual Report on Form 10-K/A for the fiscal year ended June 30, 2014 filed on February 23, 2015.

Earnings Per Share, Policy [Policy Text Block]	Net Income (Loss) per Common Share

	Net income (loss) per common share is computed pursuant to section 260-10-45 of the FASB Accounting Standards Codification. Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants, convertible preferred stock, and convertible debentures.

	The following table shows the number of potentially outstanding dilutive common shares excluded from the diluted net income (loss) per common share calculation as they were anti-dilutive:

		Potentially Outstanding Dilutive Common Shares
		For the		For the
		Nine Months		Nine Months
		Ended		Ended
		31-Mar-15		31-Mar-14

	Stock options		535,715		535,715

	Warrants		5,959,527		8,870,065

	Total potentially outstanding dilutive common shares		6,495,242		9,405,780

	In addition, the Company has issued Convertible Debentures, to investors. A portion of the interest required to be paid on the debentures had been paid in shares of the Company’s $0.001 par value common stock (“ Interest Shares”) according to the terms of the Debenture. No additional Interest Shares are required to be issued under the terms of the debenture. The Company will need to issue 571,428 warrants on January 15, 2016 relating to the additional interest to be paid on the Series B debentures. Coupon interest payable quarterly related to the Series B Debentures is payable in cash or shares of Common Stock at the average of the open and close value on the date such interest payment is due at the option of the Holder. The Holders have elected to receive coupon interest in cash.

	At March 31, 2015, the estimated number of potentially dilutive shares of the Company’s common stock into which the Series B debentures can be converted based upon the conversion price of $3.50 is 1,714,286. At March 31, 2015 the number of potential dilutive shares of the Company’s common stock into which the Series C debentures can be converted based upon the conversion provisions contained in the debenture is 952,381.

	The Company has also issued 3,406,085 of $0.001 par value Preferred A shares to investors and others as of March 31, 2015. Only in the event of a “change of control” of the Company, each Series A preferred share is convertible to 3.5 shares of its new common stock. A “Change of Control” is defined as an event in which the Company’s shareholders become 60% or less owners of a new entity as a result of a change of ownership, merger or acquisition. In the absence of a Change of Control event, the Series A stock is not convertible into Common Stock, and does not carry any dividend rights or any other financial effects. At March 31, 2015, the estimated number of potentially dilutive shares of the Company’s common stock into which these Series A Preferred shares can be converted into is 11,921,298, and is not included in diluted earnings per share since the shares are contingently convertible only upon a Change of Control.

	Pursuant to the Redemption provisions of the Series C Debentures, the Company, at its sole option, shall have the right, but not the obligation, to repurchase the Debenture at any time prior to the Maturity Date (the “Redemption”). If the Company intends to repurchase the Debenture, and if the closing bid price of the Common Stock is greater than $5.25 on the Redemption Date, unless the Holder, on or prior to the Redemption Date, elects to receive the “Redemption Payment”, as that term is defined herein, the Company shall pay to the Holder: (i) 952,381 shares of Common Stock in consideration of the exchange of the principal amount of the Debenture; and (ii) any and all accrued coupon interest. If on or prior to the Redemption Date, the Holder elects to receive the Redemption Payment, or the closing bid price of the Common Stock is less than $5.25, the Company shall issue to the Holder: (i) the principal amount of the Debenture; (ii) any accrued coupon interest; (iii) additional interest of 7% per annum for the period from the date of issuance of the Debenture to the Redemption Date; and (iv) warrants to purchase 619,048 shares of Common Stock which shall expire in three years from the date of issuance at an exercise price of $6.05 per share of Common Stock (the “Redemption Warrants”, and collectively with (i) – (iii), the “Redemption Payment”). The Company shall use its best efforts to register the shares underlying the Redemption Warrants under a “shelf” registration statement, provided same is available to the Company, in accordance with the provisions of the Securities Act.

	The following represents a reconciliation of the numerators and denominators of the basic and diluted per share calculations for income from continuing operations:

		For the three months ended				For the nine months ended
		March 31,		March 31,		March 31,		March 31,
		2015		2014		2015		2014
	Calculation of basic loss per share of common stock:

	Net (loss) income attributable to common stockholders	$	-251,018	$	1,323,854	$	-1,280,462	$	-6,601,163

	Denominator for basic weighted average shares of common stock		56,941,122		53,318,736		56,356,105		50,307,984

	Basic (loss) income per share of common stock	$	0	$	0.02	$	-0.02	$	-0.13

	Calculation of diluted loss per share of common stock:

	Net (loss) income attributable to common stockholders	$	-251,018	$	1,323,854	$	-1,280,462	$	-6,601,163

	Add: Income impact of assumed conversion of Debentures		-696,103		-2,502,430		-2,740,562		-

	Net (loss) income attributable to common stockholders plus assumed conversions	$	-947,121	$	-1,178,576	$	-4,021,024	$	-6,601,163

	Denominator for basic weighted average shares of common stock		56,941,122		53,318,737		56,356,105		50,307,984

	Incremental shares from assumed conversions of Debentures payable		2,666,667		1,714,286		2,666,667		-

	Denominator for diluted weighted average shares of common stock		59,607,788		55,033,023		59,022,772		50,307,984

	Diluted (loss) income per share of common stock	$	-0.02	$	-0.02	$	-0.07	$	-0.13

	Series B Debentures were excluded from the loss per share calculation for the three and nine months ended March 31, 2014 because the impact is anti-dilutive.

New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Pronouncements

	In June 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-12, "Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period." This ASU requires a reporting entity to treat a performance target that affects vesting and that could be achieved after the requisite service period as a performance condition, and apply existing guidance under the Stock Compensation Topic of the ASC as it relates to awards with performance conditions that affect vesting to account for such awards. The provisions of this ASU are effective for interim and annual periods beginning after December 31, 2015. The Company is currently evaluating the impact of this ASU.

	In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”). ASU 2014-15 is intended to define management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. Specifically, ASU 2014-15 provides a definition of the term substantial doubt and requires an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). It also requires certain disclosures when substantial doubt is alleviated as a result of consideration of management’s plans and requires an express statement and other disclosures when substantial doubt is not alleviated. The new standard will be effective for reporting periods beginning after December 15, 2016, with early adoption permitted. Management is currently evaluating the impact of the adoption of ASU 2014-14 on the Company’s financial statements and disclosures.

	In April 2015, the FASB issued ASU 2015-03, Interest - Imputation of Interest (Subtopic 835-30), “Simplifying the Presentation of Debt Issuance Costs,” which requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. This ASU requires retrospective adoption and will be effective for fiscal years beginning after December 15, 2015 and for interim periods within those fiscal years. We expect the adoption of this guidance will not have a material impact on our financial statements.

Restatement_of_Previously_Issu1

Restatement of Previously Issued Financial Statements (Tables)	9 Months Ended
	Mar. 31, 2015
Accounting Changes and Error Corrections [Abstract]
Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]	The impact of the above adjustment to the line items in our unaudited financial statements as of March 31, 2014 and for the three and nine months ended March 31, 2014 are summarized in the tables below:

	Balance Sheet Data

		March 31, 2014		Net Adjustments		March 31, 2014
		(Unaudited)				(Unaudited)
		As Originally Reported				As Restated

	LONG TERM LIABILITIES:
	Debentures payable - Series B	$	3,887,378	$	-	$	3,887,378
	Derivative liability -Series B		3,824,986		-		3,824,986
	Derivative liability -warrants		-		4,082,131		4,082,131
	Total Long Term Liabilities		7,712,364		4,082,131		11,794,495

	Total Liabilities		8,920,548		4,082,131		13,002,679

	STOCKHOLDERS' EQUITY:
	Additional paid-in capital		78,531,194		-5,740,540		72,790,654
	Accumulated deficit		-46,559,356		1,658,409		-44,900,947

	Total Stockholders' Equity	$	32,029,392	$	-4,082,131	$	27,947,261

	Statements of Operations
	(Unaudited)

		For the Three Months				For the Three Months		For the Nine Months				For the Nine Months
		Ended				Ended		Ended				Ended
		March 31, 2014		Net Adjustments		March 31,2014		March 31, 2014		Net Adjustments		March 31,2014
		As Originally Reported				As Restated		As Originally Reported				As Restated
	OPERATING EXPENSES
	Research and development	$	625,737	$	-	$	625,737	$	2,930,436	$	-	$	2,930,436
	Refund credit research and development costs		-		-				-		-
	General and administrative		607,628		-		607,628		1,943,123		-		1,943,123

	Total operating expenses		1,233,365		-		1,233,365		4,873,559		-		4,873,559

	LOSS FROM OPERATIONS		-1,233,365		-		-1,233,365		-4,873,559		-		-4,873,559

	OTHER INCOME (EXPENSE):
	Interest income		54,789		-		54,789		78,850		-		78,850
	Interest expense		-2,725,716		-		-2,725,716		-2,972,216		-		-2,972,216
	Discount on convertible debentures		-143,051		-		-143,051		-419,305		-		-419,305
	Change in fair market value of derivatives		3,752,933		1,618,264		5,371.20		-73,342		1,658,409		1,585,067

	Other income (expense), net		938,955		1,618,264		2,557,219		-3,386,013		1,658,409		-1,727,604

	(LOSS ) INCOME BEFORE INCOME TAX PROVISION		-294,410		1,618,264		1,323,854		-8,259,572		1,658,409		-6,601,163

	INCOME TAX PROVISION		-		-		-		-		-

	NET (LOSS) INCOME	$	-294,410	$	1,618,264	$	1,323,854	$	-8,259,572	$	1,658,409	$	-6,601,163

	NET (LOSS) INCOME PER COMMON SHARE
	- Basic	$	-0.01			$	0.02	$	-0.16				-0.13
	- Diluted	$	-0.01			$	-0.02	$	-0.16			$	-0.13

	Weighted average common shares outstanding
	- Basic		53,318,736				53,318,736		50,307,984				50,307,984
	- Diluted		53,318,736				55,033,023		50,307,984				50,307,984

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	9 Months Ended
Summary of Significant Accounting Policies (Tables)	Mar. 31, 2015
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	The following table shows the number of potentially outstanding dilutive common shares excluded from the diluted net income (loss) per common share calculation as they were anti-dilutive:

		Potentially Outstanding Dilutive Common Shares
		For the		For the
		Nine Months		Nine Months
		Ended		Ended
		31-Mar-15		31-Mar-14

	Stock options		535,715		535,715

	Warrants		5,959,527		8,870,065

	Total potentially outstanding dilutive common shares		6,495,242		9,405,780


	The following represents a reconciliation of the numerators and denominators of the basic and diluted per share calculations for income from continuing operations:

		For the three months ended				For the nine months ended
		March 31,		March 31,		March 31,		March 31,
		2015		2014		2015		2014
	Calculation of basic loss per share of common stock:

	Net loss attributable to common stockholders	$	-251,018	$	-1,323,854	$	-1,280,462	$	-6,601,163

	Denominator for basic weighted average shares of common stock		56,941,122		53,318,736		56,356,105		50,307,984

	Basic loss per share of common stock	$	0	$	-0.02	$	-0.02	$	-0.13

	Calculation of diluted loss per share of common stock:

	Net loss attributable to common stockholders	$	-251,018	$	1,323,854	$	-1,280,462	$	-6,601,163

	Add: Income impact of assumed conversion of Debentures		-696,103		-		-2,740,562		-

	Net loss attributable to common stockholders plus assumed conversions	$	-947,121	$	-1,323,854	$	-4,021,024	$	-6,601,163

	Denominator for basic weighted average shares of common stock		56,941,122		50,031,363		56,356,105		50,307,984

	Incremental shares from assumed conversions of Debentures payable		2,666,667		-		2,666,667		-

	Denominator for diluted weighted average shares of common stock		59,607,788		50,031,363		59,022,772		50,307,984

	Diluted loss per share of common stock	$	-0.02	$	-0.02	$	-0.07	$	-0.13

Related_Party_Transactions_Tab

Related Party Transactions (Tables)	9 Months Ended
Related Party Transactions (Tables)	Mar. 31, 2015
Related Party Transactions [Abstract]
Schedule of Related Party Transactions [Table Text Block]		For the nine months ended
		March 31, 2015
	During the reporting period, the Company acquired 1 Controls Drive Shelton Ct from Inno-Haven, LLC	$	4,222,549

	During the reporting period, Inno-Haven, LLC, acquired property and equipment on behalf of the Company from third party vendors and sold such property and equipment, at cost, to the Company	$	-

	During the reporting period, TheraCour Pharma, Inc. acquired property and equipment on behalf of the Company from third party vendors and sold such property and equipment, at cost, to the Company	$	222,582

	Prepaid Expense (Accounts Payable) Related Party

		As of		As of
		March 31, 2015		June 30, 2014
	Pursuant to an Exclusive License Agreement and an Additional License Agreement we entered into with TheraCour Pharma, Inc., (TheraCour), the Company was granted exclusive licenses in perpetuity for technologies developed by TheraCour for the virus types: HIV, HCV, Herpes, Asian (bird) flu, Influenza and rabies, and others. In consideration for obtaining these exclusive licenses, we agreed: (1) that TheraCour can charge its costs (direct and indirect) plus no more than 30% of direct costs as a Development Fee and such development fees shall be due and payable in periodic installments as billed. (2) we will pay $25,000 per month for usage of lab supplies and chemicals from existing stock held by TheraCour, (3) we will pay $2,000 per month or actual costs, whichever is higher for other general and administrative expenses incurred by TheraCour on our behalf. Prepaid Expense (Accounts payable) due TheraCour Pharma Inc. (including a two (2) month security advance):	$	66,100	$	-49,455

	Research and Development Costs Paid to Related Parties

		For the three months ended				For the nine months ended
		March 31,		March 31,		March 31,		March 31,
		2015		2014		2015		2014

	Development fees and other costs charged by and paid to TheraCour Pharma, Inc. pursuant to exclusive License Agreements between TheraCour and the Company for the development of the Company’s drug pipeline. No royalties are due TheraCour from the Company at March 31, 2015 and 2014	$	398,407	$	391,628	$	1,688,547	$	1,315,753

	Long Term Debenture Payable to a Director

		March 31, 2015		June 30, 2014

	Series B Convertible Debentures - Milton Boniuk	$	4,000,000	$	4,000,000

	Series C Convertible Debentures: - Milton Boniuk		5,000,000		-

	Total Long Term Debentures Payable to a Director	$	9,000,000	$	4,000,000

Property_and_Equipment_Tables

Property and Equipment (Tables)	9 Months Ended
Property and Equipment (Tables)	Mar. 31, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Property and equipment, stated at cost, less accumulated depreciation consisted of the following:

		March 31,		June 30,
		2015		2014

	Building GMP Facility	$	8,376,336	$	3,099,780

	Office Equipment		30,048		30,048

	Furniture and Fixtures		1,400		1,400

	Lab Equipment		3,893,110		3,605,514

	Total Property and Equipment		12,300,894		6,736,742

	Less Accumulated Depreciation		-1,393,982		-1,239,986
	Property and Equipment, Net	$	10,906,912	$	5,496,756

Trademark_and_Patents_Tables

Trademark and Patents (Tables)	9 Months Ended
Trademark and Patents (Tables)	Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets [Table Text Block]	Trademark and patents, stated at cost, less accumulated amortization consisted of the following:

		March 31,		June 30,
		2015		2014

	Trademarks and Patents	$	458,954	$	458,954
	Less Accumulated Amortization		-57,149		-50,696
	Trademarks and Patents, Net	$	401,805	$	408,258

Convertible_Debentures_Tables

Convertible Debentures (Tables)	9 Months Ended
Convertible Debentures (Tables)	Mar. 31, 2015
Series B Debentures [Member]
Schedule of Long-term Debt Instruments [Table Text Block]	The following table presents the balance of the Debenture payable – Series B, net of discount at March 31, 2015 and June 30, 2014. The debt discount is being accreted to interest expense over the term of the debenture:

		March 31,		June 30,
		2015		2014


	Proceeds	$	6,000,000	$	6,000,000
	Debt discount for bifurcated derivative		-2,735,310		-2,735,310
			3,264,690		3,264,690

	Amortization of debt discount		1,261,039		772,878

	Debenture payable - Series B, net	$	4,525,729	$	4,037,568

Series C Debentures [Member]
Schedule of Long-term Debt Instruments [Table Text Block]	The following represents the balance of the Debenture payable – Series C, net of discount at March 31, 2015:

	Proceeds	$	5,000,000
	Debt discount
	Series A Preferred		-1,152,297
	Embedded derivative		-1,879,428
			1,968,275

	Amortization of debt discount for the nine months ended March 31, 2015		372,293

	Balance at March 31, 2015	$	2,340,568

Equity_Transactions_Tables

Equity Transactions (Tables)	9 Months Ended
Equity Transactions (Tables)	Mar. 31, 2015
Stockholders' Equity Note [Abstract]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	For the nine months ended March 31, 2015, the Company estimated the fair value of the warrants granted quarterly to the Scientific Advisory Board on the date of grant using the Black-Scholes Option-Pricing Model with the following weighted-average assumptions:

	Expected life (year)	4

	Expected volatility	37.44% -45.84	%

	Expected annual rate of quarterly dividends	0	%

	Risk-free rate(s)	1.20 - 1.67	%

Stock_Options_and_Warrants_Tab

Stock Options and Warrants (Tables)	9 Months Ended
Stock Options and Warrants (Tables)	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	The following table presents the activity of stock options issued for the nine months ended March 31, 2015 as follows:

	Stock Options	Number of		Weighted		Weighted		Aggregate
		Shares		Average		Average		Intrinsic
				Exercise Price		Remaining		Value ($)
				per share ($)		Contractual
						Term (years)
	Outstanding at June 30, 2014		535,715	$	0.35		1.23	$	2,094,643
	Granted		-		-		-		-
	Exercised		-		-		-		-
	Expired		-		-		-		-
	Canceled		-		-		-		-
	Outstanding at March 31,2015		535,715	$	0.35		0.48.	$	996,424

Stock Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]
	Stock Warrants	Number of		Weighted		Weighted		Aggregate
		Shares		Average		Average		Intrinsic Value
				Exercise		Remaining		($)
				Price		Contractual Term
				per share		(years)
				($)
	Outstanding and exercisable at June 30, 2014		8,894,355	$	5.01		2.78	$	2,278,458

	Granted		51,444		4.18		-		-
	Exercised		1,926,656		3.5		-		-
	Expired		1,059,616		-		-		-
	Canceled		-		-		-		-
	Outstanding and exercisable at March 31, 2015		5,959,527	$	5.15		3.34	$	19,004

Fair_Value_Measurement_Tables

Fair Value Measurement (Tables)	9 Months Ended
Fair Value Measurement (Tables)	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]	At March 31, 2015 and June 30, 2014, the estimated fair values of the liabilities measured on a recurring basis are as follows:

		Fair Value Measurements at
		March 31, 2015:

		(Level 1)		(Level 2)		(Level 3)

	Derivative liability – Series B debentures	$	-		-	$	930,940
	Derivative liability – Series C debentures		-		-		809,305
	Derivative liability – warrants		-		-		4,611,472
	Total derivatives	$	-	$	-	$	6,351,717

		Fair Value Measurements at
		June 30, 2014 (Restated):

		(Level 1)		(Level 2)		(Level 3)

	Derivative liability – Series B debentures	$	-	$	-		5,699,703
	Derivative liability - warrants		-		-		5,235,682
	Total derivatives	$	-	$	-	$	10,935,385

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following tables present the activity for liabilities measured at estimated fair value using unobservable inputs for the nine months ended March 31, 2015:

		Fair Value Measurement
		Using Significant
		Unobservable Inputs
		Derivative liability – Series B		Derivative liability – Series C		Derivative liability - warrant

	Beginning balance at July 1, 2014	$	5,699,703	$	-	$	5,235,682
	Additions during the year		-		1,879,428		-
	Change in fair value		-4,768,763		-1,070,123		-624,210
	Transfer in and/or out of Level 3		-		-		-
	Ending balance at March 31, 2015	$	930,940	$	809,305	$	4,611,472

Organization_and_Nature_of_Bus1

Organization and Nature of Business (Details Textual) (USD $)	9 Months Ended	0 Months Ended
	Mar. 31, 2015	Feb. 15, 2010	Jun. 30, 2014
Product Information [Line Items]
Entity Incorporation, State Country Name	Colorado
Entity Incorporation, Date Of Incorporation	25-Jul-00
Business Acquisition, Name of Acquired Entity	Edot-com.com, Inc.
Business Acquisition, Date of Acquisition Agreement	12-May-05
Common stock, shares issued	57,150,415		54,620,993
Common stock, shares, outstanding	57,150,415		54,620,993
ECMM [Member]
Product Information [Line Items]
Common Stock Shares Issued Prorata Basis	4,000
Stock Issued During Period, Shares, New Issues	80,000,000
Common stock, shares issued	100,000,000
Common stock, shares, outstanding	100,000,000
Business Acquisition, Percentage of Voting Interests Acquired	80.00%
Series A Preferred Stock [Member]
Product Information [Line Items]
Preferred stock, shares issued		2,000,000
Preferred stock		$2,000
Convertible Preferred Stock, Terms of Conversion	The Series A Preferred Stock is convertible, only upon sale or merger of the company, or the sale of or license of substantially all of the Company’s intellectual property, into shares of the Company’s common stock at the rate of 3.5 shares of common stock for each share of Series A Preferred Stock.
Stockholders' Equity, Reverse Stock Split		(adjusted for the 3.5 to 1 reverse split)

Restatement_of_Previously_Issu2

Restatement of Previously Issued Financial Statements (Details) (USD $)	Mar. 31, 2015	Jun. 30, 2014	Mar. 31, 2014
LONG TERM LIABILITIES:
Debentures payable	$0	$5,000,000
Total Long Term Liabilities	13,218,014	19,972,953	11,794,495
Total Liabilities	13,741,443	20,490,692	13,002,679
STOCKHOLDERS' EQUITY:
Additional paid-in capital	84,982,686	75,212,888	72,790,654
Accumulated deficit	-53,181,861	-51,901,400	-44,900,947
Total Stockholders' Equity	31,861,382	23,369,303	27,947,261
Series B Debentures [Member]
LONG TERM LIABILITIES:
Debentures payable	4,525,729	4,037,568	3,887,378
Derivative liability	930,940	5,699,703	3,824,986
Series C Debentures [Member]
LONG TERM LIABILITIES:
Debentures payable	2,340,568	0
Derivative liability	809,305	0
Warrant [Member]
LONG TERM LIABILITIES:
Derivative liability			4,082,131
Restatement Adjustment [Member]
LONG TERM LIABILITIES:
Total Long Term Liabilities			4,082,131
Total Liabilities			4,082,131
STOCKHOLDERS' EQUITY:
Additional paid-in capital			-5,740,540
Accumulated deficit			1,658,409
Total Stockholders' Equity			-4,082,131
Restatement Adjustment [Member] \| Series B Debentures [Member]
LONG TERM LIABILITIES:
Debentures payable			0
Derivative liability			0
Restatement Adjustment [Member] \| Warrant [Member]
LONG TERM LIABILITIES:
Derivative liability			4,082,131
Scenario, Previously Reported [Member]
LONG TERM LIABILITIES:
Total Long Term Liabilities			7,712,364
Total Liabilities			8,920,548
STOCKHOLDERS' EQUITY:
Additional paid-in capital			78,531,194
Accumulated deficit			-46,559,356
Total Stockholders' Equity			32,029,392
Scenario, Previously Reported [Member] \| Series B Debentures [Member]
LONG TERM LIABILITIES:
Debentures payable			3,887,378
Derivative liability			3,824,986
Scenario, Previously Reported [Member] \| Warrant [Member]
LONG TERM LIABILITIES:
Derivative liability			$0

Restatement_of_Previously_Issu3

Restatement of Previously Issued Financial Statements (Details 1) (USD $)	3 Months Ended		9 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
OPERATING EXPENSES
Research and development	$546,464	$625,737	$2,274,310	$2,930,436
General and administrative	576,173	607,628	2,352,115	1,943,123
Total operating expenses	1,122,637	1,233,365	4,626,425	4,873,559
LOSS FROM OPERATIONS	-1,122,637	-1,233,365	-4,626,425	-4,873,559
OTHER INCOME (EXPENSE):
Interest income	35,009	54,789	156,035	78,850
Interest expense	-1,920,268	-2,725,716	-2,412,712	-2,972,216
Discount on convertible debentures	-297,276	-143,051	-860,454	-419,305
Change in fair market value of derivatives	3,054,154	5,371,197	6,463,095	1,585,067
Other income (expense), net	871,619	2,557,219	3,345,964	-1,727,604
(LOSS ) INCOME BEFORE INCOME TAX PROVISION	-251,018	1,323,854	-1,280,461	-6,601,163
INCOME TAX PROVISION	0	0	0	0
NET (LOSS) INCOME	-251,018	1,323,854	-1,280,461	-6,601,163
NET (LOSS) INCOME PER COMMON SHARE
Basic (in dollars per share)	$0	$0.02	($0.02)	($0.13)
Diluted (in dollars per share)	($0.02)	($0.02)	($0.07)	($0.13)
Weighted average common shares outstanding
Basic (in shares)	56,941,122	53,318,736	56,356,105	50,307,984
Diluted (in shares)	59,607,788	55,033,023	59,022,772	50,307,984
Scenario, Previously Reported [Member]
OPERATING EXPENSES
Research and development		625,737		2,930,436
Refund credit research and development costs		0		0
General and administrative		607,628		1,943,123
Total operating expenses		1,233,365		4,873,559
LOSS FROM OPERATIONS		-1,233,365		-4,873,559
OTHER INCOME (EXPENSE):
Interest income		54,789		78,850
Interest expense		-2,725,716		-2,972,216
Discount on convertible debentures		-143,051		-419,305
Change in fair market value of derivatives		3,752,933		-73,342
Other income (expense), net		938,955		-3,386,013
(LOSS ) INCOME BEFORE INCOME TAX PROVISION		-294,410		-8,259,572
INCOME TAX PROVISION		0		0
NET (LOSS) INCOME		-294,410		-8,259,572
NET (LOSS) INCOME PER COMMON SHARE
Basic (in dollars per share)		($0.01)		($0.16)
Diluted (in dollars per share)		($0.01)		($0.16)
Weighted average common shares outstanding
Basic (in shares)		53,318,736		50,307,984
Diluted (in shares)		53,318,736		50,307,984
Restatement Adjustment [Member]
OPERATING EXPENSES
Research and development		0		0
Refund credit research and development costs		0		0
General and administrative		0		0
Total operating expenses		0		0
LOSS FROM OPERATIONS		0		0
OTHER INCOME (EXPENSE):
Interest income		0		0
Interest expense		0		0
Discount on convertible debentures		0		0
Change in fair market value of derivatives		1,618,264		1,658,409
Other income (expense), net		1,618,264		1,658,409
(LOSS ) INCOME BEFORE INCOME TAX PROVISION		1,618,264		1,658,409
INCOME TAX PROVISION		0		0
NET (LOSS) INCOME		$1,618,264		$1,658,409

Restatement_of_Previously_Issu4

Restatement of Previously Issued Financial Statements (Details Textual) (USD $)	3 Months Ended		9 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Change in Accounting Estimate [Line Items]
Net Income (Loss) Attributable To Parent	($251,018)	$1,323,854	($1,280,461)	($6,601,163)
Restatement Adjustment [Member]
Change in Accounting Estimate [Line Items]
Adjustments to Additional Paid in Capital, Other				4,082,131
Net Income (Loss) Attributable To Parent		1,618,264		1,658,409
Warrant [Member] \| Restatement Adjustment [Member]
Change in Accounting Estimate [Line Items]
Increase (Decrease) in Derivative Liabilities				$4,082,131

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details)	9 Months Ended
Summary of Significant Accounting Policies (Details)	Mar. 31, 2015	Mar. 31, 2014
Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	6,495,242	9,405,780
Stock Options [Member]
Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	535,715	535,715
Warrants [Member]
Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	5,959,527	8,870,065

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Details 1) (USD $)	3 Months Ended		9 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Calculation of basic loss per share of common stock:
Net (loss) income attributable to common stockholders	($251,018)	$1,323,854	($1,280,462)	($6,601,163)
Denominator for basic weighted average shares of common stock	56,941,122	53,318,736	56,356,105	50,307,984
Basic (loss) income per share of common stock	$0	$0.02	($0.02)	($0.13)
Calculation of diluted loss per share of common stock:
Net (loss) income attributable to common stockholders	-251,018	1,323,854	-1,280,462	-6,601,163
Add: Income impact of assumed conversion of Debentures	-696,103	-2,502,430	-2,740,562	0
Net (loss) income attributable to common stockholders plus assumed conversions	($947,121)	($1,178,576)	($4,021,024)	($6,601,163)
Denominator for basic weighted average shares of common stock	56,941,122	53,318,736	56,356,105	50,307,984
Incremental shares from assumed conversions of Debentures payable	2,666,667	1,714,286	2,666,667	0
Denominator for diluted weighted average shares of common stock	59,607,788	55,033,023	59,022,772	50,307,984
Diluted (loss) income per share of common stock	($0.02)	($0.02)	($0.07)	($0.13)

Summary_of_Significant_Account5

Summary of Significant Accounting Policies (Details Textual) (USD $)	9 Months Ended	1 Months Ended
	Mar. 31, 2015	Mar. 31, 2015	Jun. 30, 2014	Jan. 15, 2016
Accounting Policies [Line Items]
Common Stock, Par Or Stated Value Per Share	$0.00	$0.00	$0.00
Debt Instrument, Redemption, Description	the Company, at its sole option, shall have the right, but not the obligation, to repurchase the Debenture at any time prior to the Maturity Date (the Redemption). If the Company intends to repurchase the Debenture, and if the closing bid price of the Common Stock is greater than $5.25 on the Redemption Date, unless the Holder, on or prior to the Redemption Date, elects to receive the Redemption Payment, as that term is defined herein, the Company shall pay to the Holder: (i) 952,381 shares of Common Stock in consideration of the exchange of the principal amount of the Debenture; and (ii) any and all accrued coupon interest. If on or prior to the Redemption Date, the Holder elects to receive the Redemption Payment, or the closing bid price of the Common Stock is less than $5.25, the Company shall issue to the Holder: (i) the principal amount of the Debenture; (ii) any accrued coupon interest; (iii) additional interest of 7% per annum for the period from the date of issuance of the Debenture to the Redemption Date; and (iv) warrants to purchase 619,048 shares of Common Stock which shall expire in three years from the date of issuance at an exercise price of $6.05 per share of Common Stock (the Redemption Warrants, and collectively with (i) (iii), the Redemption Payment). The Company shall use its best efforts to register the shares underlying the Redemption Warrants under a shelf registration statement, provided same is available to the Company, in accordance with the provisions of the Securities Act.
Scenario, Forecast [Member]
Accounting Policies [Line Items]
Common Stock, Par Or Stated Value Per Share				$0.00
Convertible Debentures Shares Reserved For Future issuance				571,428
Series A Convertible Preferred Stock [Member]
Accounting Policies [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$3.50	$3.50
Convertible Preferred Stock, Shares Issued upon Conversion	11,921,298	11,921,298
Preferred Stock, Shares Issued	3,406,085	3,406,085	3,193,079
Preferred Stock, Par Value (In Dollars Per Share)	$0.00	$0.00	$0.00
Common Stock [Member] \| Series B Convertible Debentures [Member]
Accounting Policies [Line Items]
Debt Conversion, Converted Instrument, Shares Issued		1,714,286
Debt Instrument, Convertible, Conversion Price	$3.50	$3.50
Common Stock [Member] \| Series C Convertible Debentures [Member]
Accounting Policies [Line Items]
Debt Conversion, Converted Instrument, Shares Issued		952,381

Financial_Condition_Details_Te

Financial Condition (Details Textual) (USD $)	Mar. 31, 2015	Jun. 30, 2014	Mar. 31, 2014	Jun. 30, 2013
Financial Condition [Line Items]
Cash and cash equivalents	$33,919,404	$36,696,892	$33,265,347	$13,923,245
Retained Earnings (Accumulated Deficit)	($53,181,861)	($51,901,400)	($44,900,947)

Related_Party_Transactions_Det

Related Party Transactions (Details) (USD $)	3 Months Ended		9 Months Ended
Related Party Transactions (Details) (USD $)	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014	Jun. 30, 2014
Research and development	$546,464	$625,737	$2,274,310	$2,930,436
Due to Related Parties	9,000,000		9,000,000		4,000,000
Series B Convertible Debentures [Member]
Due to Related Parties	4,000,000		4,000,000		4,000,000
Series C Convertible Debenture [Member]
Due to Related Parties	5,000,000		5,000,000		0
Innohaven, LLC [Member] \| Option One [Member]
Due to Related Parties	4,222,549		4,222,549
Innohaven, LLC [Member] \| Option Two [Member]
Due to Related Parties	0		0
TheraCour Pharma, Inc [Member]
Net Account Payable to related party	66,100		66,100		-49,455
Research and development	398,407	391,628	1,688,547	1,315,753
Due to Related Parties	$222,582		$222,582

Related_Party_Transactions_Det1

Related Party Transactions (Details Textual) (USD $)	9 Months Ended
Related Party Transactions (Details Textual) (USD $)	Mar. 31, 2015
Related Party Transaction [Line Items]
Related Party Transaction, Description of Transaction	charge its costs (direct and indirect) plus no more than 30% of direct costs
Lab Supplies and Chemicals Fees	$25,000
Other General and Administrative Expense	$2,000

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	Mar. 31, 2015	Jun. 30, 2014
Property, Plant and Equipment [Line Items]
Building GMP Facility	$8,376,336	$3,099,780
Office Equipment	30,048	30,048
Furniture and Fixtures	1,400	1,400
Lab Equipment	3,893,110	3,605,514
Total Property and Equipment	12,300,894	6,736,742
Less Accumulated Depreciation	-1,393,982	-1,239,986
Property and Equipment, Net	$10,906,912	$5,496,756

Property_and_Equipment_Details1

Property and Equipment (Details Textual) (USD $)	1 Months Ended	9 Months Ended
Property and Equipment (Details Textual) (USD $)	Dec. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Property, Plant and Equipment [Line Items]
Depreciation		$153,996	$151,902
Acuisition And Renovation Expenses Of Manufacturing And Lab Facility	4,222,549
Closing Costs Of Facility	$81,230

Trademark_and_Patents_Details

Trademark and Patents (Details) (USD $)	Mar. 31, 2015	Jun. 30, 2014
Trademarks And Patents [Line Items]
Trademarks and Patents	$458,954	$458,954
Less Accumulated Amortization	-57,149	-50,696
Trademarks and Patents, Net	$401,805	$408,258

Trademark_and_Patents_Details_

Trademark and Patents (Details Textual) (USD $)	9 Months Ended
Trademark and Patents (Details Textual) (USD $)	Mar. 31, 2015	Mar. 31, 2014
Trademarks And Patents [Line Items]
Amortization	$6,453	$6,581

Convertible_Debentures_Details

Convertible Debentures (Details) (USD $)	9 Months Ended	12 Months Ended
Convertible Debentures (Details) (USD $)	Mar. 31, 2015	Jun. 30, 2014
Debenture payable - Series B, net	$0	$5,000,000
Series B Debentures [Member]
Proceeds	6,000,000	6,000,000
Debt discount for bifurcated derivative	-2,735,310	-2,735,310
Net Proceeds From Issuance Of Debt	3,264,690	3,264,690
Amortization of debt discount	1,261,039	772,878
Debenture payable - Series B, net	$4,525,729	$4,037,568

Convertible_Debentures_Details1

Convertible Debentures (Details 1) (USD $)	9 Months Ended
Convertible Debentures (Details 1) (USD $)	Mar. 31, 2015	Jun. 30, 2014
Balance at December 31, 2014	$0	$5,000,000
Series C Debentures [Member]
Proceeds	5,000,000
Debt discount	-1,879,428
Net Proceeds From Issuance Of Debt	1,968,275
Amortization of debt discount	372,293
Balance at December 31, 2014	2,340,568
Series A Preferred Stock [Member] \| Series C Debentures [Member]
Debt discount	($1,152,297)

Convertible_Debentures_Details2

Convertible Debentures (Details Textual) (USD $)	5 Months Ended	9 Months Ended		1 Months Ended	3 Months Ended	6 Months Ended	0 Months Ended	9 Months Ended	12 Months Ended
Convertible Debentures (Details Textual) (USD $)	Jun. 30, 2013	Mar. 31, 2015	Mar. 31, 2014	Feb. 28, 2013	Mar. 31, 2015	Dec. 31, 2014	Jul. 02, 2014	Dec. 31, 2014	Jun. 30, 2014	Jul. 17, 2014	Feb. 02, 2013
Debt Instrument [Line Items]
Common stock, par value (in dollars per share)		$0.00			$0.00				$0.00
Investment Warrants, Exercise Price	$3.50
Debt Conversion, Converted Instrument, Amount		$1,152,297	$0
Class of Warrant or Right, Exercise Price of Warrants or Rights										$3.50
Debt Instrument, Redemption, Description		the Company, at its sole option, shall have the right, but not the obligation, to repurchase the Debenture at any time prior to the Maturity Date (the Redemption). If the Company intends to repurchase the Debenture, and if the closing bid price of the Common Stock is greater than $5.25 on the Redemption Date, unless the Holder, on or prior to the Redemption Date, elects to receive the Redemption Payment, as that term is defined herein, the Company shall pay to the Holder: (i) 952,381 shares of Common Stock in consideration of the exchange of the principal amount of the Debenture; and (ii) any and all accrued coupon interest. If on or prior to the Redemption Date, the Holder elects to receive the Redemption Payment, or the closing bid price of the Common Stock is less than $5.25, the Company shall issue to the Holder: (i) the principal amount of the Debenture; (ii) any accrued coupon interest; (iii) additional interest of 7% per annum for the period from the date of issuance of the Debenture to the Redemption Date; and (iv) warrants to purchase 619,048 shares of Common Stock which shall expire in three years from the date of issuance at an exercise price of $6.05 per share of Common Stock (the Redemption Warrants, and collectively with (i) (iii), the Redemption Payment). The Company shall use its best efforts to register the shares underlying the Redemption Warrants under a shelf registration statement, provided same is available to the Company, in accordance with the provisions of the Securities Act.
Long-Term Debt, Excluding Current Maturities		0			0				5,000,000
Restricted Stock [Member]
Debt Instrument [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance											571,429
Warrant [Member]
Debt Instrument [Line Items]
Debt Instrument, Term		3 years
Derivative Liability, Noncurrent		4,611,472			4,611,472				5,235,682
Series B Convertible Debentures [Member]
Debt Instrument [Line Items]
Amortization of Debt Discount (Premium)		488,161			166,543
Proceeds from Convertible Debt	6,000,000
Debt Instrument, Term	4 years
Debt Instrument, Interest Rate, Stated Percentage									8.00%
Warrants To Be Issued In Fourth Year											571,429
Class of Warrant or Right, Exercise Price of Warrants or Rights		$3.50			$3.50						3.5
Debt Instrument, Redemption, Description				The Company can prepay the debentures, in which case the base interest rate shall increase by a 7% prepayment penalty.
Long-Term Debt, Excluding Current Maturities		6,000,000			6,000,000
Share Price		$2.25			$2.25
Debt Instrument, Debt Default, Description of Violation or Event of Default		An event of default would occur 0% of the time, increasing 1.00% per month to a maximum of 10%
Derivative Liability, Noncurrent		930,940			930,940
Projected Redemption Percentage Of Time		0.00%
Projected Annual Volatility Percentage		67.00%				75.00%
Weighted Average Discount Rate, Percent			21.86%
Series B Convertible Debentures [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Projected Redemption Percentage Of Time		5.00%
Series B Convertible Debentures [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Projected Redemption Percentage Of Time		1.00%
Series B Convertible Debentures [Member] \| Director [Member]
Debt Instrument [Line Items]
Proceeds from Convertible Debt	4,000,000
Series A Convertible Preferred Stock [Member]
Debt Instrument [Line Items]
Amortization of Debt Discount (Premium)		372,293			130,733
Debt Conversion, Converted Instrument, Shares Issued							187,000
Proceeds from Convertible Debt							1,645,606
Repayments of Other Debt							1,152,297
Debt Instrument, Unamortized Discount							1,152,297
Debt Conversion, Converted Instrument, Amount							1,879,428
Series C Convertible Preferred Stock [Member]
Debt Instrument [Line Items]
Common stock, par value (in dollars per share)							$0.00
Debt Instrument, Convertible, Conversion Price							$5.25
Debt Instrument, Convertible, Carrying Amount of Equity Component							5,000,000
Redemption On Debentures							952,381
Warrants to purchase of Common Stock							619,048
Common stock exercise price							$6.05
Series C Convertible Debenture [Member]
Debt Instrument [Line Items]
Debt Instrument, Maturity Date		30-Jun-18
Proceeds from Issuance of Debt									5,000,000
Debt Instrument, Interest Rate, Stated Percentage							10.00%
Class of Warrant or Right, Exercise Price of Warrants or Rights		$6.05			$6.05
Long-Term Debt, Excluding Current Maturities		5,000,000			5,000,000
Share Price		$2.25			$2.25
Debt Instrument, Debt Default, Description of Violation or Event of Default					An event of default would occur 0% of the time, increasing 1.00% per month to a maximum of 10%
Derivative Liability, Noncurrent		$809,305			$809,305
Projected Redemption Percentage Of Time		0.00%
Projected Annual Volatility Percentage					67.00%			75.00%
Weighted Average Discount Rate, Percent		21.86%
Closing Common Stock Bid Price							$5.25
Additional Interest Rate For Warrants							7.00%
Series C Convertible Debenture [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Projected Redemption Percentage Of Time					5.00%
Series C Convertible Debenture [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Projected Redemption Percentage Of Time					1.00%

Equity_Transactions_Details

Equity Transactions (Details)	9 Months Ended
Equity Transactions (Details)	Mar. 31, 2015
Class of Stock [Line Items]
Expected life (year)	4 years
Expected annual rate of quarterly dividends	0.00%
Maximum [Member]
Class of Stock [Line Items]
Expected volatility	45.84%
Risk-free rate(s)	1.67%
Minimum [Member]
Class of Stock [Line Items]
Expected volatility	37.44%
Risk-free rate(s)	1.20%

Equity_Transactions_Details_Te

Equity Transactions (Details Textual) (USD $)	1 Months Ended	9 Months Ended	0 Months Ended
Equity Transactions (Details Textual) (USD $)	Jul. 17, 2014	Mar. 31, 2015	Jul. 02, 2014	Jun. 30, 2014	Feb. 01, 2015
Class of Stock [Line Items]
Common stock, par value (in dollars per share)		$0.00		$0.00
Number Of Common Stock To Be Issued Upon Conversion Of Warrants		51,444
Fair Value Of Common Stock Warrant Issued During Period For Consulting Services		$52,130
Fair Value Measurements, Significant Assumptions		a. The common stock price (post-reverse split) was in the range $2.72 to $2.29; b. The calculated weighted average number of shares of common stock in the period; c. A 5.36% premium over the common shares for the voting preferences; d. The calculated weighted average number of total voting shares and the monthly shares representing voting rights of 4.896% to 5.046% of the total; e. The conversion value is based on an assumption for calculation purposes only of a Change of Control in 4 years from March 1, 2013 and a remaining restricted term of 2.08 to 1.92 years; f. 32.61% to 31.42% restricted stock discount (based on a restricted stock analysis and call-put analysis curve: 78.63% to 69.38% volatility, 0.674% to 0.47% risk free rate) applied to the converted common.
Class of Warrant or Right, Exercise Price of Warrants or Rights	$3.50
Interest Payable, Current		375,000		0
Common Stock, Shares Authorized		85,714,285		85,714,285
Warrants Issued To Purchase Of Common Stock	1,926,656
Aggregate Purchase Price Of Warrants	6,743,297
Conversion of Stock, Description		the converted value to common at a ratio of 1:3.5.
Minimum [Member]
Class of Stock [Line Items]
Stock Issued During Period Price Per Share		$3.62
Maximum [Member]
Class of Stock [Line Items]
Stock Issued During Period Price Per Share		$5.04
Warrant [Member]
Class of Stock [Line Items]
Common Stock, Shares Authorized	3,071,986
Director [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross		10,453
Stock Issued During Period, Value, Share-based Compensation, Gross		33,750
Consulting Services [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross		20,881
Stock Issued During Period, Value, Share-based Compensation, Gross		82,360
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross		23,148
Stock Issued During Period, Value, Share-based Compensation, Gross		181,363
Series A Convertible Preferred Stock [Member] \| Long-Term Debentures Payable [Member]
Class of Stock [Line Items]
Stock Issued During Period, Value, Issued For Services			1,152,297
Debt Conversion, Converted Instrument, Shares Issued			187,000
Series A Convertible Preferred Stock [Member] \| Consulting Services [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross		2,858
Stock Issued During Period, Value, Share-based Compensation, Gross		24,474
Series B Debentures [Member]
Class of Stock [Line Items]
Common stock, par value (in dollars per share)					$0.00
Interest Payable, Current					$1,502,869
Board Of Directors Authorized Number Of Shares					571,433

Stock_Options_and_Warrants_Det

Stock Options and Warrants (Details) (USD $)	9 Months Ended	12 Months Ended
Stock Options and Warrants (Details) (USD $)	Mar. 31, 2015	Jun. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Remaining Contractual Term, (year) Granted	0 years
Equity Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding	535,715
Number of Shares, Granted	0
Number of Shares, Exercised	0
Number of Shares, Expired	0
Number of Shares, Canceled	0
Number of Shares, Outstanding	535,715	535,715
Weighted Average Exercise Price per share , Outstanding	$0.35
Weighted Average Exercise Price per share, Granted	$0
Weighted Average Exercise Price per share, Exercised	$0
Weighted Average Exercise Price per share, Expired	$0
Weighted Average Exercise Price per share, Canceled	$0
Weighted Average Exercise Price per share , Outstanding	$0.35	$0.35
Weighted Average Remaining Contractual Term, (year) Exercised	0 years
Weighted Average Remaining Contractual Term, (year) Expired	0 years
Weighted Average Remaining Contractual Term, (year) Canceled	0 years
Weighted Average Remaining Contractual Term, (year) Outstanding	5 months 23 days	1 year 2 months 23 days
Aggregate Intrinsic Value, Outstanding	$996,424	$2,094,643
Aggregate Intrinsic Value, Granted	0
Aggregate Intrinsic Value, Exercised	0
Aggregate Intrinsic Value, Expired	0
Aggregate Intrinsic Value, Canceled	$0

Stock_Options_and_Warrants_Det1

Stock Options and Warrants (Details 1) (USD $)	9 Months Ended	12 Months Ended
Stock Options and Warrants (Details 1) (USD $)	Mar. 31, 2015	Jun. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Remaining Contractual Term, (year) Granted	0 years
Stock Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding	8,894,355
Number of Shares, Granted	51,444
Number of Shares, Exercised	1,926,656
Number of Shares, Expired	1,059,616
Number of Shares, Canceled	0
Number of Shares, Outstanding	5,959,527	8,894,355
Weighted Average Exercise Price per share , Outstanding	$5.01
Weighted Average Exercise Price per share, Granted	$4.18
Weighted Average Exercise Price per share, Exercised	$3.50
Weighted Average Exercise Price per share, Expired	$0
Weighted Average Exercise Price per share, Canceled	$0
Weighted Average Exercise Price per share , Outstanding	$5.15	$5.01
Weighted Average Remaining Contractual Term, (year) Granted	0 years
Weighted Average Remaining Contractual Term, (year) Exercised	0 years
Weighted Average Remaining Contractual Term, (year) Expired	0 years
Weighted Average Remaining Contractual Term, (year) Canceled	0 years
Weighted Average Remaining Contractual Term, (year) Outstanding	3 years 4 months 2 days	2 years 9 months 11 days
Aggregate Intrinsic Value, Outstanding	$19,004	$2,278,458
Aggregate Intrinsic Value, Granted	0
Aggregate Intrinsic Value, Exercised	0
Aggregate Intrinsic Value, Expired	0
Aggregate Intrinsic Value, Cancelled	$0

Stock_Options_and_Warrants_Det2

Stock Options and Warrants (Details Textual)	9 Months Ended
Stock Options and Warrants (Details Textual)	Mar. 31, 2015
June 30, 2015 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Exercisable	277,149
Warrants Expiration Date	30-Jun-15
June 30, 2016 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Exercisable	68,571
Warrants Expiration Date	30-Jun-16
June 30, 2017 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Exercisable	68,571
Warrants Expiration Date	30-Jun-17
June 30 2018 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Exercisable	68,570
Warrants Expiration Date	30-Jun-18
June 30, 2019 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Exercisable	5,476,666
Warrants Expiration Date	30-Jun-19

Fair_Value_Measurement_Details

Fair Value Measurement (Details) (USD $)	Mar. 31, 2015	Jun. 30, 2014
Warrant [Member]
Derivative Liability, Noncurrent	$4,611,472	$5,235,682
Fair Value, Inputs, Level 1 [Member]
Derivative Liability, Noncurrent	0	0
Fair Value, Inputs, Level 1 [Member] \| Derivative liability - Series B debentures [Member]
Derivative Liability, Noncurrent	0	0
Fair Value, Inputs, Level 1 [Member] \| Derivative liability - Series C debentures [Member]
Derivative Liability, Noncurrent	0
Fair Value, Inputs, Level 1 [Member] \| Warrant [Member]
Derivative Liability, Noncurrent	0	0
Fair Value, Inputs, Level 2 [Member]
Derivative Liability, Noncurrent	0	0
Fair Value, Inputs, Level 2 [Member] \| Derivative liability - Series B debentures [Member]
Derivative Liability, Noncurrent	0	0
Fair Value, Inputs, Level 2 [Member] \| Derivative liability - Series C debentures [Member]
Derivative Liability, Noncurrent	0
Fair Value, Inputs, Level 2 [Member] \| Warrant [Member]
Derivative Liability, Noncurrent	0	0
Fair Value, Inputs, Level 3 [Member]
Derivative Liability, Noncurrent	6,351,717	10,935,385
Fair Value, Inputs, Level 3 [Member] \| Derivative liability - Series B debentures [Member]
Derivative Liability, Noncurrent	930,940	5,699,703
Fair Value, Inputs, Level 3 [Member] \| Derivative liability - Series C debentures [Member]
Derivative Liability, Noncurrent	809,305
Fair Value, Inputs, Level 3 [Member] \| Warrant [Member]
Derivative Liability, Noncurrent	$4,611,472	$5,235,682

Fair_Value_Measurement_Details1

Fair Value Measurement (Details 1) (USD $)	9 Months Ended
Fair Value Measurement (Details 1) (USD $)	Mar. 31, 2015
Warrant [Member]
Begining Balance	$5,235,682
Additions during the year	0
Change in fair value	-624,210
Transfer in and/or out of Level 3	0
Ending Balance	4,611,472
Derivative liability - Series C debentures [Member]
Begining Balance	0
Additions during the year	1,879,428
Change in fair value	-1,070,123
Transfer in and/or out of Level 3	0
Ending Balance	809,305
Derivative liability - Series B debentures One [Member]
Begining Balance	5,699,703
Additions during the year	0
Change in fair value	-4,768,763
Transfer in and/or out of Level 3	0
Ending Balance	$930,940

Commitments_and_Contingencies_

Commitments and Contingencies (Details Textual) (USD $)	1 Months Ended	9 Months Ended
	Feb. 28, 2011	Mar. 31, 2015	Mar. 31, 2014
	sqft	Mar. 31, 2015	Mar. 31, 2014
Commitments and Contingencies [Line Items]
Space For Office and Laboratory	7,000
Monthly Base Rent	$8,695
Lease Expiration Date	28-Feb-11
Operating Leases, Rent Expense, Net		$78,255	$78,255